IVDR impact on manufacturing
At Europlaz, we’ve seen how the shift from IVDD to IVDR has reshaped planning, industrialisation and manufacturing for OEMs. This updated guide explains the changes, what they mean in 2026, and how manufacturers can use the extended timelines wisely, without falling behind.
Understanding the shift from IVDD to IVDR and Its impact on manufacturing
Under the old IVDD system, most IVDs could be self‑certified by manufacturers, with only about 20% needing a Notified Body. This limited oversight no longer matched modern diagnostics. As a result, IVDR introduced a far stricter framework, with around 80% of devices now requiring Notified Body involvement.
To prevent supply shortages caused by limited Notified Body capacity, the EU extended transition periods for legacy devices under Regulation (EU) 2024/1860, published in June 2024. This amendment pushed final compliance deadlines out to 2027–2029, depending on classification. [dxrx.io]
These extensions offer valuable breathing space, but they come with strict conditions. Manufacturers must maintain IVDD compliance, avoid significant design changes, keep products safe, and apply IVDR‑compliant quality systems.
IVDR manufacturing deadlines: what OEMs need to know in 2026
Thanks to the 2024 amendments, the final IVDR transition deadlines for legacy devices have moved beyond the previously feared 2025 “cliff edge”:
- Class D devices: allowed on the market until 31 December 2027
- Class C devices: until 31 December 2028
- Class B and Class A (sterile): until 31 December 2029
However, these dates only apply if manufacturers meet critical earlier milestones. Most importantly, an IVDR‑compliant Quality Management System must have been in place by 26 May 2025, regardless of device class.
From an IVDR manufacturing perspective, this means:
- Production processes must already align with IVDR expectations
- Validation and documentation cannot be left until the final deadline
- Manufacturing partners must operate within robust quality frameworks early on
Extended deadlines reduce pressure but they do not remove responsibility.
Why IVDR manufacturing requirements are still critical despite extended timelines
It’s tempting to view the extension as extra time to pause. In reality, the extended timelines are designed to support a controlled and orderly transition, not delay progress.
IVDR manufacturing brings stricter expectations around:
- IQ/OQ/PQ validation
- Detailed batch‑level records
- Clear change control procedures
- Long‑term supplier stability
- Life‑cycle‑based documentation rather than one‑time approval
In parallel, EUDAMED is entering phased mandatory use from 2026. Manufacturing teams must now prepare for:
- UDI‑ready labelling
- Improved data capture and traceability
- Stronger links between production records and regulatory reporting
For OEMs, treating IVDR manufacturing as a late‑stage issue often leads to avoidable rework and launch delays.
Preparing for IVDR manufacturing: using the extended timelines wisely
1. Build IVDR compliance into manufacturing early
Processes that meet IVDR expectations from the outset reduce the risk of re‑validation later.
2. Strengthen documentation gradually
Extended timelines allow documentation to evolve alongside production, rather than being rushed at the end.
3. Stabilise materials and suppliers
Supplier changes under IVDR may trigger additional scrutiny. Stability supports smoother approvals.
4. Prepare for UDI and EUDAMED requirements
Labelling and traceability requirements are manufacturing responsibilities, not just regulatory tasks.
OEMs that align industrialisation with IVDR manufacturing needs earlier tend to protect both timelines and budgets.
How Europlaz supports IVDR manufacturing at scale
- Setting up IVDR‑aligned manufacturing documentation
- Ensuring cleanroom production meets regulatory requirements
- Managing traceability and UDI‑ready labelling
- Providing strong validation (IQ/OQ/PQ)
- Supporting stable supply chains
- Ensuring records are audit‑ready for Notified Bodies
Extended deadlines don’t reduce expectations but they do allow manufacturers to prepare thoroughly and avoid rushed transitions. We help you use that time wisely.
A critical focus for 2026
With the right manufacturing partner, you can move through the transition confidently, avoiding the stress of last‑minute compliance and ensuring market continuity.
Ready to strengthen your IVDR manufacturing strategy?
Contact us today to discuss how we can support your manufacturing, documentation and validation needs under IVDR.
We’re ready to help you move forward confidently.
FAQs
What does IVDR mean for manufacturing?
IVDR increases expectations around how IVDs are manufactured, not just how they are designed. Manufacturers must demonstrate validated processes, strong traceability, stable supply chains and clear documentation that supports consistent production over time.
Do the extended IVDR deadlines mean manufacturers can delay action?
No. While final compliance deadlines have moved to 2027–2029 for many legacy devices, key requirements such as an IVDR‑compliant quality management system still apply. Manufacturing processes need to align with IVDR expectations well before final certification.
Why is IVDR manufacturing important for OEMs?
IVDR manufacturing affects production timelines, validation effort and market readiness. OEMs that address manufacturing requirements early are more likely to avoid delays during scale‑up and Notified Body review.
How does IVDR affect cleanroom manufacturing?
IVDR places greater emphasis on consistency, documentation and traceability, all core elements of cleanroom manufacturing. Processes must be clearly validated and controlled to meet regulatory expectations.
How can a contract manufacturer support IVDR manufacturing compliance?
An experienced contract manufacturer can embed IVDR requirements into industrialisation, validation and production workflows, helping OEMs prepare manufacturing processes that are audit‑ready and scalable.
Download our brochure
Curious to learn more? Download our brand-new company brochure to discover how Europlaz is evolving and what it means to you.
Discover Europlaz
Our UK-based ISO 13485 certified and FDA-compliant cacility means that we have complete control of the process, from under one roof. We are flexible, and resourceful, and can take on projects of any size. Our clients range from small start-ups to international blue chip medical device suppliers.
